So Jin Lee, Pharm.D., Ph.D. is a pharmacometrician and Co-founder/CEO/CTO of APLUS Simulation based in Seoul, Korea, specializing in AI-powered PK/PD and semi-mechanistic modeling for biologics, bispecific antibodies, and cell and gene therapy. She also serves as an Affiliated Professor at Sungkyunkwan University School of Pharmacy, where she teaches pharmacometrics and clinical pharmacology. Dr. Lee has led more than a decade of modeling-supported drug development across global regulatory landscapes, contributing to IND/NDA/BLA submissions to MFDS, FDA, and EMA while advancing NAMs-aligned in silico methodologies. Her research focuses on quantitative translational modeling and AI integration for MIDD, with multiple first-author publications and invited lectures at national and international conferences. She is actively pioneering AI-enabled frameworks to accelerate human-centered, non-animal drug development approaches globally.

Henry Purbrick is a final-year CSIRO Industry PhD candidate at the University of Western Australia and Harry Perkins Institute of Medical Research, undertaking his research in collaboration with Dimerix, a Melbourne-based biopharmaceutical company. Using live-cell biosensors, amongst other in vitro methodologies, his project aims to discover unique signalling mechanisms of novel GCPR heteromers as potential therapeutic targets for complex inflammatory diseases. Beyond his laboratory research, Henry completed an internship with Dimerix, where he explored translational strategies for potential pipeline candidates. Actively involved in committees, Henry is the current Chair of the Perkins Student Committee, and student representative of the ASCEPT Industry & Innovation special interest group.

Xin Liu is a Ph.D. candidate in Pharmacometrics at Fudan University (since 2024). His research focuses on the development of pharmacological models and the population analysis of pharmacokinetic (PK) and pharmacodynamic (PD) data. He has applied pharmacometric methodologies across multiple therapeutic areas, with primary emphasis on bacterial infections and neuroscience. His work supports model-informed precision dosing (MIPD) in special populations, such as critically ill patients, and advances model-informed drug development (MIDD) through active collaboration with local biotechnology companies. He has published more than five SCI papers as first author in leading journals, including the International Journal of Antimicrobial Agents and the Journal of Affective Disorders.

Zhaoyi Yang, MD, is an Associate Chief Pharmacist and Master Supervisor with extensive experience in clinical pharmacology. As a Principal Investigator, Dr. Yang has led over 20 Phase I clinical trials, contributing significantly to the advancement of early-stage drug development. In addition to clinical work, Dr. Yang holds multiple academic and professional positions. He is a member of the Clinical Pharmacology Committee of the Chinese Pharmacological Society and a young member of the Drug Clinical Trials Committee of the same society. At the regional level, he serves as Vice Chairman of the Anti-inflammatory and Immune Pharmacology Committee and as a member and Deputy Secretary-General of the Clinical Pharmacology Committee of the Anhui Pharmacological Society. He is also a standing member of the Drug Clinical Evaluation Committee and part of the Drug Clinical Research and Evaluation Special Committee of the Anhui Medical Doctor Association. Dr. Yang’s work bridges clinical research, pharmacology, and academic leadership, advancing safe and effective therapeutics in China.

Dr. D. Figueredo received her B.A. degree (1995, Biochemistry) from Faculty of Biology, Havana University, Cuba, and both her MSc (1995, Biomedicine) and PhD (1999 Pharmaceutical Sciences) degree from National Center for Scientific Research in Havana, and most of the results were done in the Department of Toxicology at the Free University in Amsterdam. Postdoctoral training in Molecular Toxicology and pharmacology was completed at the Faculty of Pharmacy in Toronto, Canada. She has been referee of scientific journals related with pharmacology. Other previous academic appointments include lecturer in different international meeting. She has been the recipient of National Award of Pharmacology twice from the Cuban Pharmacology Society. She worked as Expert for the evaluation of preclinical platform in South Africa. (CSIR). She is the focal point to the World Health Organization network for regulatory cooperation of herbal medicines (IRCH). She is a membership committee of International Union of Pharmacology (IUPHAR). She is the secretary of Latin-American Network of Pharmacogenetic. She is currently the Vice president of Cuban Pharmacology Society. At present she works in the Cuba Regulatory Agency as senior researcher, she is in charge of the evaluation of safety and efficacy of traditional, integrative and complementary medicines for registering. Dr. Remirez research is described in over 60 published research reports.

Non is a PhD student at Bangor University’s Centre for Health Economics and Medicines Evaluation (CHEME). She holds a BSc in Biomedical Sciences from The University of Manchester and an MScRes from Bangor University, where she explored how digital health solutions could support patients in adhering to their medicines. Her PhD research focuses on medication adherence during the run-in phase of clinical trials, under the supervision of Professor Dyfrig Hughes, Professor Bernard Vrijens, and Associate Professor Daniel Wright. Her doctoral studies are funded by the Medical Research Council Trials Methodology Research Partnership Doctoral Training Programme (MRC TMRP DTP).